bioRxiv Science⌕ Search

Biology subjects

Rasch, M. G.

Publications and source records attributed to Rasch, M. G..

3 recordsLinked to original sources

pH-sensitive binder design with Proton-PottsMPNN

Physiological compartments span a wide pH range, from blood plasma near pH 7.4 through the mildly acidic tumor microenvironment to the acidified endosome and lysosome, and binders whose affinity responds to these differences underpin recycling antibodies, catalytic extracellular degraders and tumor-conditional therapeutics. Such binders are still obtained mainly by combinatorial histidine scanning and display selection, which is laborious and yields few transferable design rules. Recent computational approaches have enabled the design of pH-sensitive binders that engage at physiological pH and release under acidic conditions, by introducing histidines at key positions so that protonation generates electrostatic repulsion, evaluated through physics-based calculations. However, because the design model has no explicit representation of protonation state, it cannot shape the residues around a titratable site to favor one state over the other, leaving pH sensitivity to be screened for rather than specified. Here we present Proton-PottsMPNN, a sequence-design model that explicitly represents the protonated and deprotonated states of histidine, aspartate and glutamate as distinct sequence tokens. Because protonation state is specified rather than inferred, the model redesigns the microenvironment around a titratable residue so that the chosen protonation state is energetically favored over its alternative. Using Proton-PottsMPNN we designed a library of 8,407 de novo PD-L1 candidate binders in which sequence-structure compatibility and protonation state preference were designed jointly under a single energy function, with no structure-prediction filtering applied. The full library was synthesized and displayed on yeast, then screened against PD-L1 across a series of pH values by fluorescence- and magnetic-activated cell sorting, recovering 237 and 288 unique pH-dependent designs respectively. Transition pH values spanned 4.0 to 5.8, and switches were centered on protonated aspartate and glutamate as well as histidine. Recovered designs showed a stronger model preference for their designed protonation state than designs from the same backbone that were not recovered, and this preference was strongest in the designs that required the most acidic conditions to bind. Proton-PottsMPNN therefore designs binders that engage PD-L1 under acidic conditions fully de novo, directly from a specified protonation state.

biophysics↗

Brain-wide mapping of proglucagon expression in mice identifies fasting-responsive GLP-1 neurons in the posterior hypothalamic nucleus

ObjectiveGlucagon-like peptide-1 (GLP-1), a peptide neurotransmitter in the brain, is synthesized from proglucagon, encoded by the glucagon gene (Gcg). Besides medullary GLP-1 neurons, Gcg-expressing neuron populations were identified in the olfactory bulb and basolateral amygdala. However, several lines of evidence suggest that additional Gcg neuron populations might exist. MethodsWe conducted a brain-wide mapping of Gcg-expressing cells by fluorescent in situ hybridization in C57BL/6J and FVB/Ant mice. Proglucagon and GLP-1 expression were studied with immunofluorescence. We characterized a Gcg-Cre;tdTomato mouse line and studied the expression of proglucagon-processing enzymes in Gcg-expressing neuron populations. We used adeno-associated virus-mediated tracing in Gcg-Cre mice to map the projections of hypothalamic Gcg neurons. ResultsGcg-expressing neuron populations were identified in the olfactory bulb, claustrum, piriform cortex, basolateral amygdala, posterior hippocampus, posterior hypothalamic nucleus (PH), periaqueductal gray/dorsal raphe, and dorsal nucleus of the lateral lemniscus. These neurons express lower Gcg mRNA levels than medullary GLP-1 neurons. Proglucagon and GLP-1-immunoreactivity (C-terminus) were detected in almost all Gcg-expressing neuron populations, along with the mRNAs for prohormone convertases 1/3 and 2, enzymes generating GLP-1 or glucagon, respectively. Fasting markedly increased Gcg mRNA, proglucagon and GLP-1 synthesis in the PH. PH Gcg neurons project densely to the ventral and intermediate lateral septum, preoptic region, ventrolateral preoptic nucleus, lateral hypothalamus and zona incerta, establishing close contacts with both GLP-1 receptor-positive and -negative neurons. ConclusionsProglucagon is expressed in 9 distinct neuron populations. Feeding status regulates GLP-1 synthesis in PH neurons that likely control feeding- or energy balance-related functions.

neuroscience↗

Evaluation of Gremlin-1 as a therapeutic target in metabolic dysfunction-associated steatohepatitis

Gremlin-1 has been implicated in liver fibrosis in metabolic dysfunction-associated steatohepatitis (MASH) via inhibition of bone-morphogenetic protein (BMP) signalling and has thereby been identified as a potential therapeutic target. Using rat in vivo and human in vitro and ex vivo model systems of MASH fibrosis, we show that neutralisation of Gremlin-1 activity with monoclonal therapeutic antibodies does not reduce liver inflammation or liver fibrosis. Still, Gremlin-1 was upregulated in human and rat MASH fibrosis, but expression was restricted to a small subpopulation of COL3A1/THY1+ myofibroblasts. Lentiviral overexpression of Gremlin-1 in LX-2 cells and primary hepatic stellate cells led to changes in BMP-related gene expression, which did not translate to increased fibrogenesis. Furthermore, we show that Gremlin-1 binds to heparin with high affinity, which prevents Gremlin-1 from entering systemic circulation, prohibiting Gremlin-1-mediated organ crosstalk. Overall, our findings suggest a redundant role for Gremlin-1 in the pathogenesis of liver fibrosis, which is unamenable to therapeutic targeting.

pathology↗